Fund Holdings — GREAT POINT PARTNERS LLC

Total Portfolio Value:
$641.64M
Total Bought:
$273.33M
Total Sold:
$233.72M
Net Transaction:
+$39.61M
Notable People:
Ronald Marc Panzier
Securities
▲▼
SharesValue
Q4 2023
▲▼
Q1 2024
▲▼
Change
▲▼
Q4 2023
▲▼
Q1 2024
▲▼
Weight (%)
▲▼
Change
▲▼
Neurogene Inc.(NGNE)994,2291,004,291+10,062$19.27M$51.12M7.97%+$31.85M
Alpine Immune Sciences Inc3,703,4331,128,499-2,574,934$70.59M$44.73M6.97%-$25.85M
UroGen Pharma Ltd.(URGN)2,620,5452,620,5450$39.31M$39.31M6.13%$0
ABIVAX Société AnonymeADS(ABVX)1,550,0002,488,483+938,483$16.59M$35.59M5.55%+$19.00M
Evolus, Inc.(EOLS)2,000,0002,450,000+450,000$21.06M$34.30M5.35%+$13.24M
Pliant Therapeutics, Inc.(PLRX)1,823,1841,851,864+28,680$33.02M$27.59M4.30%-$5.43M
Apogee Therapeutics Inc400,000400,0000$11.18M$26.58M4.14%+$15.40M
Aerovate Therapeutics Inc1,037,690887,690-150,000$23.48M$26.25M4.09%+$2.77M
Viridian Therapeutics, Inc.(VRDN)01,335,000+1,335,000$0$23.38M3.64%+$23.38M
Anaptysbio Inc976,981976,9810$20.93M$22.00M3.43%+$1.07M
Esperion Therapeutics Inc Ne08,000,000+8,000,000$0$21.44M3.34%+$21.44M
Insmed Incorporated(INSM)225,912775,585+549,673$7.00M$21.04M3.28%+$14.04M
Arcellx Inc
COMMON STOCK
48,264300,000+251,736$2.68M$20.86M3.25%+$18.19M
Xenon Pharmaceuticals Inc.(XENE)600,000456,148-143,852$27.64M$19.64M3.06%-$8.00M
Mind Medicine Mindmed Inc02,000,000+2,000,000$0$18.80M2.93%+$18.80M
Dianthus Therapeutics, Inc.(DNTH)0625,000+625,000$0$18.75M2.92%+$18.75M
Outlook Therapeutics, Inc.(OTLK)01,480,000+1,480,000$0$17.67M2.75%+$17.67M
Amicus Therapeutics Inc
COM
1,280,5001,495,500+215,000$18.17M$17.62M2.75%-$553.3K
Ocular Therapeutix, Inc.(OCUL)700,0001,728,723+1,028,723$3.12M$15.73M2.45%+$12.61M
Dynavax Technologies Corp01,264,920+1,264,920$0$15.70M2.45%+$15.70M
Cytokinetics, Incorporated(CYTK)500,000202,202-297,798$41.74M$14.18M2.21%-$27.57M
Optinose Inc8,839,9398,786,318-53,621$11.40M$12.83M2.00%+$1.42M
Jasper Therapeutics, Inc.(JSPR)0407,550+407,550$0$11.97M1.86%+$11.97M
Intra-Cellular Therapies Inc110,607150,000+39,393$7.92M$10.38M1.62%+$2.46M
Merus N V20,000223,288+203,288$550.0K$10.05M1.57%+$9.50M
Vistagen Therapeutics, Inc.(VTGN)1,858,7351,858,7350$9.55M$9.81M1.53%+$260.2K
Terns Pharmaceuticals Inc1,309,9751,309,9750$8.50M$8.59M1.34%+$91.7K
Immunocore Holdings plcADS(IMCR)293,000115,000-178,000$20.02M$7.47M1.16%-$12.54M
Autolus Therapeutics plcADS(AUTL)01,166,667+1,166,667$0$7.44M1.16%+$7.44M
Puma Biotechnology, Inc.(PBYI)1,093,2731,343,628+250,355$4.73M$7.12M1.11%+$2.39M
Zura Bio LimitedCL A(ZURA)3,295,0002,757,740-537,260$15.39M$7.09M1.10%-$8.30M
Helix Acquisition Corp IiCL A0500,000+500,000$0$5.20M0.81%+$5.20M
Spyre Therapeutics, Inc.(SYRE)125,000125,0000$2.69M$4.74M0.74%+$2.05M
Kyverna Therapeutics, Inc.(KYTX)0150,000+150,000$0$3.73M0.58%+$3.73M
Arvinas, Inc.(ARVN)234,08271,113-162,969$9.63M$2.94M0.46%-$6.70M
Alkermes plcSHS(ALKS)875,0440-875,044$24.27M$0—-$24.27M
Axsome Therapeutics, Inc.(AXSM)4,9630-4,963$395.0K$0—-$395.0K
Karuna Therapeutics Inc30,2500-30,250$9.57M$0—-$9.57M
Mural Oncology Pub Ltd Co11,5090-11,509$68.1K$0—-$68.1K
Rapt Therapeutics Inc1,099,7530-1,099,753$27.33M$0—-$27.33M
Sarepta Therapeutics, Inc.(SRPT)80,0000-80,000$7.71M$0—-$7.71M
Tourmaline Bio Inc672,8850-672,885$17.62M$0—-$17.62M
Ultragenyx Pharmaceutical Inc.(RARE)648,0000-648,000$30.99M$0—-$30.99M
Vaxcyte, Inc.(PCVX)360,0000-360,000$22.61M$0—-$22.61M
Page 1 of 1
GREAT POINT PARTNERS LLC — 13F Holdings — Q1 2024 | TickerTrail